Oral News and Research

RSS

IASLC lauds FDA approval of alectinib for lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease.

24 Dec 2015

Bioactive glass may help prolong life of composite tooth fillings

A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.

23 Dec 2015

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding.

23 Dec 2015

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

23 Dec 2015

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

22 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

The American College of Cardiology has launched a new STS/ACC TAVR In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space.

22 Dec 2015

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis.

21 Dec 2015

Periodontal disease may increase breast cancer risk

Postmenopausal women with periodontal disease were more likely to develop breast cancer than women who did not have the chronic inflammatory disease. A history of smoking significantly affected the women's risk.

21 Dec 2015

Australian researchers develop new technique to combat chronic bacterial infections in hospitals

One of the scourges of infections in hospitals – biofilms formed by bacteria that stick to each other on living tissue and medical instruments, making them harder to remove – can be tricked into dispersing with the targeted application of nanoparticles and heat, researchers have found.

21 Dec 2015

Poor outlook for ICH associated with novel oral anticoagulants

Haematoma expansion, disability and death are common among patients who have intracerebral haemorrhage while taking novel oral anticoagulants, a study in JAMA Neurology shows.

18 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Study examines effect of nonoperative treatment for appendicitis

It is too early to change the standard treatment of appendicitis in U.S. adults to initial antibiotic therapy only, rather than surgical removal of the appendix, or appendectomy, authors of a new systematic review study conclude.

18 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

One of the most common causes of healthcare-associated infections, candidiasis is a serious, life-threatening fungal infection that needs to be treated early, aggressively and appropriately, note updated guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases.

17 Dec 2015

Louisville researchers move closer to potential treatment for gum disease

University of Louisville researchers recently received a patent on a synthetic biochemical compound and its variants, moving science closer to a treatment for gum disease. This discovery could lead to the formulation of a mouth rinse or tooth varnish to prevent the pathogen, P. gingivalis from colonizing in the mouth and establishing itself orally.

17 Dec 2015

Tris announces FDA approval of first-ever ER chewable tablet

Tris Pharma, Inc. is pleased to announce that the U.S. Food and Drug Administration approved the first-ever extended-release (ER) chewable tablet, capping off a highly productive year with three Tris-developed NDAs approved in a calendar year.

16 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Oral News and Research

IASLC lauds FDA approval of alectinib for lung cancer treatment

Bioactive glass may help prolong life of composite tooth fillings

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

SciClone plans to pursue development of SGX942 in the Greater China market

Periodontal disease may increase breast cancer risk

Australian researchers develop new technique to combat chronic bacterial infections in hospitals

Poor outlook for ICH associated with novel oral anticoagulants

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Study examines effect of nonoperative treatment for appendicitis

Novel strategies on the way for difficult-to-treat head and neck cancer

Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

Louisville researchers move closer to potential treatment for gum disease

Tris announces FDA approval of first-ever ER chewable tablet

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News